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We apply the methods of optimal experimental design to a differential equation model for epi-
dermal growth factor receptor (EGFR) signaling, trafficking, and down-regulation. The model
incorporates the role of a recently discovered protein complex made up of the E3 ubiquitin ligase,
Cbl, the guanine exchange factor (GEF), Cool-1 (β-Pix), and the Rho family G protein Cdc42.
The complex has been suggested to be important in disrupting receptor down-regulation [1, 2]. We
demonstrate that the model interactions can accurately reproduce the experimental observations,
that they can be used to make predictions with accompanying uncertainties, and that we can apply
ideas of optimal experimental design to suggest new experiments that reduce the uncertainty on
unmeasurable components of the system.
I. INTRODUCTION
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor which becomes
activated upon binding of its ligand, epidermal growth factor (EGF), and signals via phosphorylation of
various effectors [3]. Besides sending signals to downstream effectors, the activated EGFR also will initialize
endocytosis which is followed by either degradation or recycling of the receptor. These are the normal
receptor down-regulation processes. Persistence of activated receptor on the cell surface can lead to aberrant
signaling and transformation of cells [4]. In addition, a variety of tumor cells exhibit overexpressed or
hyperactivated EGF receptor [5, 6], indicative of the failure of normal receptor down-regulation.
We concern ourselves with building a mathematical model of the receptor endocytosis, recycling, degrada-
tion and signaling processes that can reproduce experimental data and incorporates the effects of regulating
proteins that themselves become active after EGF stimulation. The schematic for the model is shown in
Fig. 1. In particular, we examine the roles of the GEF, Cool-1, and the GTPase, Cdc42 that have re-
cently been discovered to be important for EGFR homeostasis [1, 2] through their interaction with the E3
ubiquitin ligase, Cbl. There is evidence for two interaction mechanisms which disrupt the normal receptor
down-regulation.
The first mechanism involves the formation of a complex between active Cool-1, active Cdc42 and Cbl.
After activation of the receptor, Cool-1 becomes phosphorylated through a Src - FAK phosphorylation
cascade. Phosphorylated Cool-1 has GEF activity and in turn activates Cdc42 by catalyzing the exchange
of GDP for GTP. Unlike other GEFs however, activated Cool-1 can remain bound to its target, Cdc42, [2]
and can then form a complex with Cbl (mediated through Cool-1 binding), effectively sequestering Cbl from
the receptor. Therefore the internalization and degradation of the receptor is inhibited and its growth signal
is maintained. (We use the ERK pathway as a readout on the receptor mitogenic signal.) The second
mechanism is based on the findings of [1] that activated Cool-1 can directly bind to Cbl on the receptor and
block endocytosis in a manner we hypothesize be analogous to the action of Sprouty2 [7].
To maintain normal receptor signaling, we postulate it is crucial that deactivation of Cool-1 and subsequent
dissociation of the Cbl, Cool-1 and Cdc42 complex occur. Then Cbl can induce receptor internalization and
ubiquitin tag it for degradation in the lysosome. Internalized receptor lacking ubiquitin moieties can be
returned to the cell surface from the early endosome via the recycling pathway.
The role of Cbl in the degradation mechanism for the receptor has been understood for some time [8, 9, 10].
However, its function in mediating endocytosis still remains controversial (e.g. [11, 12, 13, 14, 15]) as the
receptor can be internalized through more than one endocytic pathway. We do not address that issue here
but rather we assume in our model that Cbl association and activation is necessary for endocytosis, whether
through a CIN85-endophilin interaction [16] or through ubiquitination of the receptor [15] and therefore we
do not include a separate Cbl-independent endocytosis pathway. The overall set of these protein-protein
interactions is summarized in Fig. 1 (we also incorporate phosphatases in the model to act on the various
phosphorylated species, but this is not shown in the network figure). There is a significant overlap between
our model and previous models of EGF receptor signaling and/or trafficking, [17, 18, 19, 20]. Since we
wish to focus on the role of the Cool-1/Cdc42 proteins within the network and to demonstrate the utility
of optimal experimental design, we leave out some of the known intermediate reactions involved in the
MAPK and EGFR-Src activation pathways, preferring a “lumped” description which is more computationally
manageable.
FIG. 1: Schematic diagram showing the set of interactions in the model of EGFR signaling, endocytosis and down-
regulation (see also [1]). Phosphatases are not shown.
The goals of this manuscript are to demonstrate how a modeling approach can be used to
(a) refine the necessary set of interactions in the biological network,
(b) make predictions on unmeasured components of the system with good precision and
(c) reduce the prediction uncertainty on components that are difficult to measure directly, by using the
methods of optimal experimental design.
II. METHODS
A. Mathematical model, parameter and prediction uncertainties
Before we introduce the algorithms needed to address the design question, we define the model and data in
more detail. Our differential equation model for EGFR signaling and down-regulation contains 56 unknown
biochemical constants: 53 unknown rate and Michaelis Menten constants (where they can be found, initial
estimates were drawn from the literature), and 3 unknown initial conditions which we found useful to vary.
The dynamical variables are comprised of 41 separate chemical species, including complexes. The data
consist entirely of time series in the form of Western blots. (The data both come from the lab of the co-
authors and from the literature, see supplementary information for details.) We have been careful to select
data only on NIH-3T3 cells, and in experimental conditions where the cell has been serum-starved prior to
EGF stimulation, to prevent activation events not related to the EGFR ligand binding. Most of the time
series data are over a period less than a few hours which allows us to ignore transcriptional processes.
Since we have no information on most of the biochemical constants, we must infer them from the data.
Therefore we optimize a cost function which measures the discrepancy of simulated data from the real data,
C(θ) =
D∑
α=1
mα∑
i=1
(
yα(tαi, θ)− dαi
σαi
)2
(1)
where α is an index on the D measured species, mα is the number of time points on species α, y is the
trajectory of the differential equation model, θ is a vector of the logarithm of the biochemical constants, dαi
is the measured value at time tαi for species α and σαi is the error on the measured value. In other words, we
have a standard weighted least squares problem to reduce the discrepancy of the model output to the data
by varying θ. (We use the logarithm of the biochemical constants as it allows us to apply an unconstrained
optimization method while maintaining the positivity constraint and it removes the discrepancies between
biochemical values that have naturally different scales in the problem). As absolute numbers of proteins
in the network cannot be accurately measured, data sets measuring activities of proteins are fit up to an
arbitrary multiplicative scale factor, which adds parameters to the model not of direct inferential interest
(nuisance parameters). Where the relative quantity of a species can be measured (normalized by the level
before EGF stimulation for example), the output of the differential equations are similarly scaled by an
appropriate common factor.
After the model has been successfully fit to the experimental data, we have a parameter estimate θˆ which
in general will have large covariances, approximated by the inverse of the Fisher information matrix (FIM).
The FIM is defined as
M = E[∂2C/∂θ2] (2)
=
D∑
α=1
mα∑
i=1
1
σαi
∂yα(tαi, θ)
∂θ
t∣∣
θˆ
1
σαi
∂yα(tαi, θ)
∂θ
∣∣
θˆ
(3)
= J tJ . (4)
where the expectation is over the distribution of errors in the data, which are assumed to be Gaussian. The
expression for the FIM above is exact when the model fits perfectly, i.e. at the best fit, the expectation of
the residuals is zero, E[yα(tαi)−di] = 0. The i
th parameter uncertainty is given by the square root of the ith
diagonal element of the inverse FIM. J = 1σαi ∂yα(tαi, θ)/∂θ|θˆ is the the sensitivity matrix of residuals with
respect to parameters at the best fit and is the analog to the design matrix in a linear regression setting.
The design space is the range of species α and of time points tαi for which measurements could be taken.
(αi is the row index of J .)
We can also make predictions on components of the trajectory (measured or unmeasured), yˆβ(t) = yβ(t, θˆ).
The variances on these quantities are given by
Var(yˆβ(t)) ≈
∂yβ(t, θ)
∂θ
t
|θˆM
−1∂yβ(t, θ)
∂θ
|θˆ (5)
The form of Eqn. 5 can be thought of as a combination of the underlying parameter uncertainty, quantified
by M−1, and the linear response of the system to the parameter uncertainty, quantified by the sensitivities.
Note that M is also computed using the sensitivities of the trajectory of the differential equations, which
we obtain by implementing the forward sensitivity equations [21]. In practice, M is close to singular if we
do not include some prior information on parameter ranges. Therefore we assume a Gaussian prior on the
parameters centered on the best fit values and with a standard deviation of log(1000). (This corresponds to
an approximately 1000-fold increase or decrease in the non-logarithmic best fit biochemical values.)
We recognize there can be other sources of uncertainty in predictions, for example if the dynamics of the
system are modeled stochastically or if there is model uncertainty that needs to be taken into account. The
former is not relevant here as the measurements we fit are not on the single cell level, but rather the average
of large populations of cells. The latter is certainly of interest but we choose an approach where model errors
are corrected during the fitting and validation process, rather than included a priori in the model definition.
Given the approximate nature of variance estimates derived from the Fisher information matrix and the
linearized model response, we supplemented these calculations with a computationally intensive Bayesian
Markov Chain Monte Carlo (MCMC) method to compute credible intervals for the predictions we make
on the model (see supplementary material). The estimates from the Bayesian MCMC approach are in
sufficient agreement with the linearized error anaylsis results that we believe the optimal experimental design
algorithms introduced below are justifiably aimed at reducing the approximate uncertainties of Eqn. 5. Using
MCMC for error estimates within the framework of the optimal design algorithms would be computationally
infeasible.
B. Optimal Experimental Design
Optimal experimental design is a technique for deciding what data should be collected from a given
experimental system such that quantities we wish to infer from the data can be done so with maximum
precision. Typically the network as shown in Fig. 1 has components that can be measured (e.g. total levels
of active Cdc42, total levels of surface receptor etc.) and components that are not directly measurable (e.g.
levels of the triple complex comprising Cool-1, Cdc42 and Cbl). Therefore we can pose the question of how to
minimize the average prediction uncertainty on some unmeasurable component of interest by collecting data
on measurable components of the system (we will use the term unmeasurable loosely for the remainder to
describe species that are between difficult and impossible to measure by standard methods). This is just one
possible design criterion, called V-optimality in the literature; other criteria involve minimizing the total
parameter uncertainty in the system (D-optimality), minimizing the uncertainty in the least constrained
direction in parameter space (E-optimality) or minimizing the maximum uncertainty in a prediction (G-
optimality) [22]. Other authors [23, 24, 25] have focused on reducing parameter uncertainty but we believe
that complex biological models, even with large amounts of precise time series data, have intrinsically large
parameter uncertainty [26, 27, 28]. On the other hand, even with no extra data collection, the uncertainty on
unmeasured time trajectories in these biological systems can be surprisingly small despite the large parameter
uncertainty [27].
By altering the form of the matrix J in Eqn. 4, by measuring different species at different times, we have
the possibility of reducing the average variance of yˆβ , which is an integral over time of the quantity defined
in Eqn. 5. We discuss the types of design and algorithms that can be used to achieve this.
A distinction must be made between starting designs and sequential designs. A starting design is one in
which no data has been collected and the experimenter would like to know what design is best to minimize a
given criterion function. Within this category are two subcategories: exact designs and continuous designs.
Exact designs refer to the optimal placement of a finite number of design points. As the the design points
need to be assigned amongst all the measurable species in the system the optimization problem is of a
combinatorial nature. There have been specific algorithms developed for this situation [22] which involve
choosing some initial design with the required number of points and then randomly modifying it by doing
exchanges, additions and deletions. More general global optimization algorithms have been applied to the
problem of finding exact designs in differential equation and regression models [29, 30].
Continuous designs refer to the selection of a design measure, η, which is equivalent to a probability density
over the design space. The advantage of assuming a continuous design is that the criterion function can then
be differentiated with respect to the design measure and tests for optimality can be derived. Asymptotically,
for a large number of design points the continuous and exact designs should coincide. For a linear model
described by y = f(t)tθ + ǫ where f(t) ∈ RN and ǫ is an error term, the FIM is
M(η) =
∫
τ
f(t)f(t)tη(x) dt
by definition of the design measure, η. However, M is a symmetric N × N matrix made up of a convex
combination of the rank one symmetric matrices, f(t)f(t)t. Therefore it can be represented by a convex
combination of at mostN(N+1)/2 design points (from Caratheodory’s Theorem) x1, . . . , xN(N+1)/2, i.e. as a
convex combination of delta function probability measures on those points. In other words even continuous
optimal designs for linear models have only a finite number of design support points [31]. In one of the
approaches that follows, we will attempt to find a continuous design by approximating the design measure
by a number of finely spaced measurement points with weights associated with each one, and we will see
that a near optimal design is in fact only supported on a small subset of those points.
Sequential designs are more relevant to the situation we consider here: experimental data have already
been collected and the model has already been fit. Therefore we can get an initial estimate for the parameters
in the system and we can evaluate the FIM. Suppose that the current design already has n points and the
current FIM isMn = J
t
nJn. The effect of adding the (n+1)
th design point (e.g. yα at time point tαi) merely
adds a single row to Jn. Therefore the new FIM is the old FIM plus a rank one update:
Mn+1 = J
t
n+1Jn+1 = J
t
nJn +
∂yα(tαi)
∂θ
∣∣
θˆ
∂yα(tαi)
∂θ
t∣∣
θˆ
.
The new inverse FIM is also a sum of terms (by applying the Sherman-Woodbury-Morrison formula [32]):
one involving the inverse of the old FIM and the other involving the sensitivity vector at the new point,
∂yα(tαi)/∂θ|θˆ, so evaluating Eqn. 5 for a large number of proposed measurements is computationally inex-
pensive.
We take an approach which is a combination of continuous design and sequential design: assume that
some initial experiments have already been carried out and we have an FIM for the system. We will then
define a cost function K(α, tαi) based on the integral of Eqn. 5 and minimize it with respect to α and tαi.
Initially the minimization looks for the best single data point to reduce the uncertainty (a sequential design
method). Once we know for which species the data needs to be collected, we can then place many potential
measurements on that species with associated weights and minimize over the weights (to mimic continuous
design methods where the set of weights is the approximate design measure).
III. RESULTS
A. Model refinements
The model was fit to 11 data sets, all Western blot data that describe various signaling, internalization
and degradation events that are triggered after receptor activation by ligand, see supplementary information
for the full set of fitted time series and description of experiments. As an example of a experimental fit with
uncertainties, we show in Fig. 2 the best fit time course and standard deviation for total surface receptor
from one of the experiments for which data was included in the model (experiment 1 in supplementary
information).
During the iterative process of fitting and model refinement we discovered certain interactions and model
parameters had to be adjusted to be consistent with the experimentally observed behavior. We briefly
summarize these adjustments below.
(1) It appears necessary to incorporate an interaction to allow the triple complex to be dissociated by a
dephosphorylation reaction. In particular a reaction was needed whereby Cool-1 within the complex could
be inactivated by its own dedicated phosphatase (a possible candidate already present in the system is
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FIG. 2: Example of experimental fit and uncertainties around the best fit trajectory (dotted lines) for total surface
receptor (in experiment 1 in supplementary information).
SHP-2, which has been shown to dephosphorylate the related Sprouty protein [33]). Without this effect, we
would not observe the complete deactivation of Cool-1 as it would be “protected” within the triple complex.
Additionally, a sensitivity analysis to determine dominant reactions in the model identified phosphatase
reactions as important (see supplementary material).
(2) Interestingly, there is an important balance between the level of receptor and Cool-1 in the system to
maintain the correct dynamics: if the level of receptor greatly exceeds the Cool-1 level, then the activated
receptor will lead indirectly to phosphorylation of Cool-1 which in turn sustains the level of signaling receptor
before significant amounts can be endocytosed. It is also essential that the protein level of Cdc42 in the
system be sufficiently high, approximately balanced with the Cbl levels as they both come together in the
triple complex. If this was not so, the greatly reduced Erk pathway signaling we see in the data set for
the Cdc42 knockdown would not be possible to reproduce (supplementary information, experiment 8). Of
course, Cdc42 is involved in many other cellular processes, so what is actually important here is the amount
available to participate in interactions with Cbl.
(3) The F28L fast cycling (hyperactive) mutant of Cdc42 has the ability to delay endogenous receptor
down-regulation for many hours beyond wild type cells (see experiment 5 in the supplementary information).
This is only possible if the binding affinity of active Cdc42 to the Cool-1-Cbl complex is strong enough to
deplete the levels of the latter and force the forward binding reaction of Cbl to activated Cool-1. This
provides a mechanism to sequester more of the Cbl protein (in both the triple complex and the Cool-1-Cbl
complex) than would otherwise be possible.
In addition to the above adjustments, we made the following observations relating to the network dynamics
and structure.
We find that given these experimental data sets, an endocytosis mechanism which is Cbl dependent and
solely acts on activated receptors is completely consistent, although we acknowledge that there is much con-
troversy in the literature as to the dominant endocytosis mechanisms and required regulators. Incorporating
a Cbl independent and Cbl dependent mechanism in the same model does not improve the fit. However,
given only a Cbl independent endocytosis mechanism, the model would be unable to account for the ap-
parent saturation of the internalization rates for overexpressed receptors (experiments 1-3 in supplementary
information) compared to endogenous receptors (experiment 5 in supplementary information). Therefore
having a Cbl dependent pathway is convenient in explaining those experimental observations, although any
number of proteins, not in the model, could cause saturation in the endocytic pathway.
Despite the apparently earlier activation of Cdc42 than its putative GEF, active Cool-1, (see experiments
10 and 11 in supplementary information) the data still supports a mechanism whereby Cdc42 activation only
occurs through Cool-1. The explanation of this effect is that the level of Cool-1 is significantly higher than
Cdc42. Then, while only a fraction of Cool-1 is being activated at early times, it is still sufficient to induce
substantial activation of Cdc42. This is an example of an apparently contradictory experimental result which
only after quantitative modeling is shown still to be consistent with the proposed mechanism. In particular,
we found there was no need to invoke another parallel activation mechanism for Cdc42 (through Vav for
example) as initially might have been assumed.
It is in the preceding way that the interactions in the system are tuned and modified to describe the
observations, and where we get insight into the mechanisms of regulation. As new experimental data are
collected, the model may have to be modified again. To decide this, the new data must be matched against
predictions from the current model. If the predictions with uncertainties suggest behavior contrary to the
observed behavior, we would need to redefine the model.
B. Predictions
Once we have a model which reproduces the experimental observations, we would like to make predictions
on unmeasured or unmeasurable components of the system. The motivation is twofold. Firstly, if we make a
prediction on a currently unmeasured component of the system which is subsequently measured, we have an
opportunity to test the validity of our model. Secondly, if we are confident in the model, we may want to test
a hypothesis about the role of an unmeasurable component in the system. If that unmeasurable component
has large uncertainties, we then need to apply the methods of experimental design to improve the situation.
We will discuss these issues in what follows.
1. Model validation
To first give an example of model validation, consider the qualitative observation in [1] that in stably
expressing v-Src cells, in conditions where Cool-1 is overexpressed, ligand-induced receptor internalization
is blocked compared to an endogenous Cool-1 control, for at least 60 minutes. The model is adjusted to
simulate the conditions of these v-Src cells by making all Src in its active form, switching off Src inactivation
and increasing the initial amounts 10-fold to mimic the stable transfection. We then predict the total surface
receptor number under the two conditions and assign uncertainties using Eqn. 5. The results are shown in
Fig. 3. The qualitative observation of strong inhibition of internalization under conditions of overexpressed
Cool-1 is verified by the model. Note that in this case the uncertainties are small enough that we can
confidently predict a large difference in the fraction of receptors on the cell surface after 60 minutes under
the two conditions. Interestingly, the model also predicts this inhibition is much weaker in cells that are not
stably expressing v-Src, essentially because the Cool-1 is not “pre-activated” and endocytosis of significant
numbers of receptors can occur before the pool of Cool-1 can become phosphorylated.
2. Optimal design for the triple complex
Another question of interest is whether the triple complex, which appears to be responsible for sequestering
Cbl and blocks receptor down-regulation when Cdc42(F28L) is expressed, also forms in appreciable amounts
in wild type cells. We would assume the answer is affirmative, as we observe a reduced downstream mitogenic
signal from the receptor under conditions of knockdown of Cool-1 or Cdc42. Since the triple complex is an
example of a species that is very difficult to obtain an accurate set of measurements for, we can test a
hypothesis about its formation in wild type cells by looking at its predicted time course, Fig. 4.
The relative amount of the triple complex is shown in Fig. 4, where the number of molecules of the
triple complex has been scaled relative to the total level of Cbl. Relative levels of complexes and the times of
formation/dissociation are more meaningful quantities than absolute numbers of molecules, which are merely
rough estimates used to initialize the simulations. The best fit trajectory for the triple complex suggests
that at a maximum over 12% of Cbl is sequestered in the complex which represents a significant proportion.
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FIG. 3: Total surface receptor numbers after EGF stimulation in stably expressing v-Src cells. Endogenous levels of
Cool-1 (dashed curve) or overexpressed Cool-1 (solid curve). The dotted lines show the uncertainties in each of the
best fit predictions
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FIG. 4: Predictions with uncertainty on the time course of the triple complex consisting of active Cool-1, Cbl and
active Cdc42. The quantity plotted is the percentage of total Cbl that is bound in the triple complex.
However the uncertainty bounds are too large to make this assertion; at the level of the lower bound, less
than 4% of Cbl is sequestered at a maximum, and the triple complex dissociates within 15 minutes. This
motivates the need for an optimal design approach. We define a criterion which is the average uncertainty
in the prediction on the triple complex. We then optimize this quantity using a sequential design approach
(therefore we need to perform only line minimizations in the time coordinate for each of the 11 measurable
species in the system) and follow up by finding an approximate optimal continuous design on that species.
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FIG. 5: (a) Trajectory of total active Cdc42 (solid line) with single sequential design measurement (marked with a
dot) and approximate continuous design weights (dotted line) to reduce the average variance of the prediction on
the Cool-1, Cbl, Cdc42 complex. The weights are optimized over 160 uniformly spaced hypothetical measurements
placed between 0 and 80 minutes on Cdc42. (b) Shows the reduction in the original uncertainty bounds resulting
from the single measurement (dotted line) and the approximate continuous design measurement (dashed line) in (a).
Compare with Fig. 4 before the addition of new measurements.
The most striking features of the optimal design results are that
1. a single measurement on total active Cdc42 can significantly reduce the variance we see in the prediction
on the triple complex, as in Fig. 5 (b)
2. even though the approximate continuous design allows for 160 hypothetical measurements on the
activity of Cdc42, the optimal design weights are concentrated to just a dozen early time points. That
is, by just taking a few measurements we can get a design very close to the optimal continuous design
for measuring total active Cdc42.
It is worth noting here that these extra measurements have little effect on the parameter uncertainty. In
Fig. 6 on the left, we show the eigenvalues of the approximate covariance matrix M−1 both before and after
the addition of the new data points. On the right is the square root of the diagonal elements of M−1, giving
the standard deviation in each parameter. As can be seen, the large parameter uncertainties are changed
little after the addition of the optimal data points. In a sense, the underlying parameter uncertainty defined
by M−1 in Eqn. 5, although large in some directions, is mostly aligned with directions where the model
sensitivity is small. Conversely, if we include hypothetical measurements on the binding and unbinding
constants involved in forming the triple complex, we find only a negligibly small decrease in the uncertainty
in the prediction of the triple complex (see supplementary information). This is not so surprising when we
understand that the uncertainty arises from the uncertainties in components of the system upstream of the
triple complex; using parameter measurements alone, almost every rate constant in the system would have
to be measured accurately to constrain the prediction [27].
3. New measurements on total active Cdc42
Further measurements were made on total activated Cdc42 in the lab by Western blotting and with no
refitting, our model was able to match the new data using a scale factor alone, see Fig. 7. (However, we cannot
consider this as a validation of our model, since prior to the inclusion of the new data, the uncertainties on
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(a) Inverse FIM eigenvalues
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FIG. 6: (a) Eigenvalues of the approximate parameter covariance matrix, M−1, with (light squares) and without
(dark circles) the optimally designed data to reduce the uncertainty of the triple complex trajectory. (b) Individual
parameter standard deviations, sorted from smallest to biggest with (light squares) and without (dark circles) the
optimally designed data. Note that the cutoff in the spectrum of eigenvalues is due to the prior information assumed
on parameters ranges. Even with prior information, 40 of the 60 parameters have uncertainties corresponding to a
greater than 20-fold increase or decrease in their non-logarithmic values.
total activated Cdc42 were very large. Any experimental observations within the uncertainty bounds would
be consistent with the model.) The uncertainties of the triple complex time course, given the real data and
the optimally weighted data, is shown in Fig. 7 (b). Importantly, given that the measured activities of total
Cdc42 were consistent with the trajectory for the optimized set of parameters, the reduction in uncertainty
of the triple complex for the real data is comparable to that for the optimally selected data and we can
make a firm conclusion that the triple complex does sequester significant amounts of the Cbl protein even
in wild type cells after EGF stimulation. Therefore it appears that the complex plays a part under normal
conditions in the EGFR homeostasis. (Note that if the new data collected showed a very different time
course than in Fig. 7, an additional re-optimization step would need to be performed before we could assess
the prediction and uncertainties for the triple complex.)
IV. DISCUSSION
We have demonstrated that by quantitatively modeling the dynamics of EGFR signaling and down-
regulation in a mammalian cell line, we are led to incorporate interactions and modify existing reactions in
order to reproduce the experimental observations. Note that these interactions are not directly tested by ex-
periments, but we can infer them from the existing data. This refinement of an existing model of interactions
and parameters is one important aspect of the modeling effort and gives insight into the underlying dynamics.
Of course, we recognize that the model as it stands will only explain the behaviors observed in the data sets
we have chosen. The addition of new experiments that test for receptor signaling from early endosomes [34],
alternative endocytic mechanisms [15], autocrine signaling [35, 36] or the interactions between members of
the erb-B family [37], for example, will require appropriate extensions of the mathematical model.
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FIG. 7: (a) Without refitting to the new total active Cdc42 data, our prediction matches the data using only a single
multiplicative factor. a.u. = arbitrary units. (b) Reduced uncertainty on the time course of the active Cool, Cbl,
and active Cdc42 complex for the optimal set of design points (dashed line) (same as Fig. 5 (b) ) and for the real
data (dotted line).
The second part of the process is to make predictions on the unmeasured or unmeasurable species of the
system, assuming that the model has been suitably refined. We suggest that for testable predictions to be
made, uncertainty estimates need to be attached to them [26]. In some cases the prediction uncertainties
are rather small, despite large parameter uncertainty. On the other hand, if some predictions show large
uncertainty, and involve species that are not directly measurable, we may then define a suitable design
criterion and suggest new experimental measurements that need to be taken to reduce that uncertainty. The
results of such an analysis are promising, in that we find a rather small number of measurements (realistic
to perform with standard molecular biology techniques) need be taken to begin to make predictions with
good precision. Given such measurements on the EGFR system, we see that the triple complex of active
Cool-1, Cbl and active Cdc42 does indeed form in appreciable quantities in wild type cells and we also get
an estimate for the time of formation and dissociation.
More generally, we believe that experimental design for reducing prediction uncertainties can play an
important role in the iterative process of model refinement and validation and can be used in the testing of
biological hypotheses.
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I. SUPPLEMENTARY INFORMATION
A. Experimental data
The experimental data are drawn from literature sources [1, 2, 3] and collected in the lab of the co-authors
(D.B., Q.F. and R.A.C.) [4]. All measurements were performed using Western blots assays on NIH-3T3 cells
and were quantified using densitometry. Within the simulation all species were represented in numbers of
molecules per cell. As many of the reactions are restricted to the cell membrane, the numbers quoted can
be thought of as effective amounts associated with the membrane. As we are only interested in relative
amounts and relative changes of protein level or activity, the absolute numbers used are of less importance
and should not be interpreted literally. Approximate receptor numbers were either reported with the source
of the experiment or were left as free parameters in the model. EGF molecule number per cell was estimated
assuming one million cells per dish and an aliquot of EGF solution of volume 3nL.
All experimental conditions involved serum starvation followed by EGF stimulation of various levels. The
Western blots were quantified by measuring average pixel density in each lane. Error bars (when not available
through replicates) were assigned typically as 20% of nominal value.
The full set of numbered experiments, corresponding to fits shown in Fig. 1, are as follows :
1. Percentage of receptors remaining on cell surface (bound or free of ligand) as a function of incubation
time with 100nM EGF. 100,000 receptors (transfected) reported initially [1].
2. Percentage of receptors remaining on cell surface as a function of incubation time with 100ng/ml EGF.
100,000 receptors (transfected) reported initially [2].
3. Percentage of receptors remaining on cell surface as a function of incubation time with 100ng/ml EGF.
275,000 receptors (transfected) reported initially [2].
4. Percentage of surface, internal and degraded EGF after pre-loading the receptors with EGF in con-
ditions that prevent internalization and then allowing internalization at time zero. There is no EGF
exposure apart from preloaded amounts. 100,000 receptors (transfected) reported initially [1].
5. Total level of EGFR as a function of incubation time with 100ng/ml EGF. 3 experimental condi-
tions: endogenous levels of Cdc42, transfection of the Cdc42F28L fast cycler, transfection of the
Cdc42(∆L8/F28L) fast cycler which is Cool-1 binding defective. 8000 receptors (endogenous) reported
initially [3].
6. Phosphorylation of Cool-1 (endogenous levels) after incubation with 100ng/ml EGF for the given times.
Number of EGFR receptors (transfected) is a free parameter [4].
7. Phosphorylation of Cool-1 (transfected) after incubation with 100ng/ml EGF for the given times.
Number of Cool-1 molecules taken as 10 fold over normal. Number of EGFR receptors (transfected)
is a free parameter [4].
8. Phosphorylation of Erk after incubation with 100ng/ml EGF for the given times. 2 experimental
conditions: endogenous levels of Cdc42 or an siRNA knockdown of Cdc42. The knockdown was
estimated to reduce the Cdc42 levels to 18 percent of normal [4]. EGFR was at endogenous levels
(assumed to be 8000 receptors as in [3]).
9. Phosphorylation of Erk after incubation with 100ng/ml EGF for the given times. 2 experimental
conditions: endogenous levels of Cool-1 or an siRNA knockdown of Cool-1. The knockdown was
estimated to reduce the Cool-1 levels to 26 percent [4]. EGFR was at endogenous levels (assumed to
be 8000 receptors as in [3]).
10. Phosphorylation of Cool-1 after incubation with 100ng/ml EGF for a range of times. EGFR num-
ber (transfected) is a free parameter. This experiment differs from the previous endogenous Cool-1
activation assay in that early time points are measured [4].
11. Activation of Cdc42 (total level of Cdc42 GTP-bound) after incubation with 100ng/ml EGF [4]. EGFR
was at endogenous levels (assumed to be 8000 receptors as in [3]).
B. Model details
The model as shown in Fig. 1 of the main text involves 41 distinct dynamical variables and 53 unknown rate
and Michaelis-Menten constants. Additionally, it was found useful to include the total number of Cool, Cbl
and Cdc42 molecules as fitted variables. Thus the optimization problem of minimizing the least squares cost
function involves 56 free parameters. Optimization was primarily carried out using a Levenberg-Marquardt
method [5], working in the natural logarithm of the biochemical constants to enforce the positivity constraint.
The fits to the experimental data are shown in Fig. 1, including the last experiment performed on active
Cdc42 which needed no re-optimization.
The system was modeled using SloppyCell, available at http://sloppycell.sourceforge.net. Sloppy-
Cell is a Python-based modeling environment which facilitates the development, simulation and optimization
of biochemical networks. The Systems Biology Markup Language (SBML) format file [6] for the model (in-
terpretable by SloppyCell and many other biochemical network simulators) and best fit parameter sets can
be obtained from the first author.
C. Parameter sensitivities
A common technique in model exploration is sensitivity analysis — determining which directions in param-
eter space are dominant in controlling the system behavior (as measured by the fit to the data in this case).
Fig. 2 shows the first three eigenvectors of the FIM which show the directions in parameter space that are
most constrained by the experimental data. Note that the most sensitive components of the pathway appear
to be related to the action of the phosphatases: a generic phosphatase for Cbl, FAK, Erk and the EGFR and
a specific phosphatase for Cool-1 (SHP-2). Furthermore, the activation pathway of Cool-1 (through FAK
and Src) appears to be quite constrained by the experimental data. Whether this is just a function of this
particular set of experimental data, or a feature of the model behavior we can test by simulating data on all
species in the system. Thus we are not biasing the sensitivity analysis towards species that have the most
data available. The principal 3 eigenvectors for the system with data simulated for all species at 2 minute
timepoints is shown in Fig. 3. The largest component in the first eigenvector is still the rate constant for
the Cool phosphatase and the rate constants of the generic phosphatase are large components in the second
eigenvector (the first eigenvector for the simulated data has a dot product of .76 with that for the real data).
D. Posterior parameter distribution
Another technique to measure the influence of parameter directions on the behavior of the system is to take
a Bayesian approach and directly sample the likelihood function for the data [7, 8]. By applying a Markov
Chain Monte Carlo (MCMC) algorithm we can build up a sample of parameter sets from the posterior
distribution. We have used the Metropolis Hastings method and run eight MCMC chains for approximately
170 hours on the model with all the experimental data (including the last experiment on total active Cdc42).
From the resulting parameter set sample, we removed correlated filtered out correlated members, leaving
approximately 5000 parameter sets as a independent draws from the posterior distribution. The posterior
sample will be more constrained in some directions than in others. The most tightly constrained directions (as
determined by doing a Principal Component Analysis (PCA) on the cloud of parameter sets) are directions
that most affect the behavior of the model. The 3 PCA axes corresponding to the most constrained directions
are shown in Fig. 4. The last principal component axis has a dot product of .96 with the first eigenvector
of the FIM, demonstrating that the linear approximation underlying the FIM is quite accurate, at least in
determining the most constrained direction.
FIG. 1: Experimental data and fits for all the experiments described in the text. Experiment 4: surface EGF (light
triangles), internal EGF (gray squares), degraded EGF (dark circles). Experiment 5: Cdc42(F28L) overexpression
(light triangles), Cdc42(F28L/DL8) (gray squares), control (black circles). Experiment 8: Cdc42 siRNA (light
triangles), control (black circles). Experiment 9: Cool-1 siRNA (gray squares), control (light triangles). All other
experiments measure a single species for a single experimental condition described in text.
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FIG. 2: Components of the first three eigenvectors of the FIM evaluated at the best fit for the EGFR model
The Bayesian approach also provides us with a tool for generating a distribution of predictions from
the posterior distribution of parameter sets. As these predictions are derived from a sampling of the full
likelihood function (compared to the Gaussian approximation assumed in the Fisher Information Matrix
approach) we would expect it to give a more accurate estimate of the true uncertainties. For comparison we
show in Fig. 5 and Fig. 6 the predictions on total surface EGFR in v-Src cells and triple complex levels in
wild type cells, using the Bayesian error estimates.
The uncertainties are sufficiently similar between the two approaches that we can justify the methods used
in the main text and can confirm the conclusions made there.
E. Parameter information and prediction uncertainty
As mentioned in the main text, the addition of the new data had little effect on the parameter uncertainty
in the system but significantly reduces the uncertainty in the prediction of the time course for the triple
complex. Conversely, assuming precise values for the rate constants involved in the formation and dissociation
of the triple complex (binding and unbinding rate constants) does little to change the uncertainty in the
prediction. This is shown in Fig. 7. The reason for the apparent insignificance of the rate constant information
is that the underlying uncertainty in the trajectory of the triple complex derives from the uncertainty in the
components from which it is comprised, rather than from the uncertainty in the rate constants for formation
and dissociation.
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FIG. 4: The last three principal component axes, in reverse order, (most tightly constrained directions) for a sample
of approximately 5000 parameter sets sampled from the posterior distribution.
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FIG. 5: The total surface receptor numbers after EGF stimulation in stably transfected v-Src cells. The two experi-
mental conditions are endogenous levels of Cool-1 (dashed curve) or overexpressed Cool-1 (solid curve). (a) The total
surface receptor trajectory is a median of all the trajectories in the posterior distribution. The uncertainties are the
boundaries of the 68% credible regions (dotted lines) to correspond with the one standard deviation errors shown in
the main text. (b) The linearized estimates, shown for comparison.
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FIG. 6: The level of the triple complex in wild type cells with endogenous EGFR. (a) Median trajectory (solid curve)
and the uncertainties given by the boundaries of the 68% credible region (dotted lines). (b) The linearized estimates,
shown for comparison. Note that the best fit trajectory in (b) is noticeably different from the median trajectory
shown in (a)
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FIG. 7: The uncertainties on the prediction of the triple complex with no formation/dissociation rate constant
information (dashed line) and assuming the relevant rate constants are known to within 5% (dotted line).
